These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33372040)

  • 21. Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
    Aliagas E; Alay A; Martínez-Iniesta M; Hernández-Madrigal M; Cordero D; Gausachs M; Pros E; Saigí M; Busacca S; Sharkley AJ; Dawson A; Palmero R; Ruffinelli JC; Padrones S; Aso S; Escobar I; Ramos R; Llatjós R; Vidal A; Dorca E; Varela M; Sánchez-Céspedes M; Fennell D; Muñoz-Pinedo C; Villanueva A; Solé X; Nadal E
    Br J Cancer; 2021 Nov; 125(10):1365-1376. PubMed ID: 34588615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
    Rodríguez-Díez E; Quereda V; Bellutti F; Prchal-Murphy M; Partida D; Eguren M; Kollmann K; Gómez de Cedrón M; Dubus P; Cañamero M; Martínez D; Sexl V; Malumbres M
    Blood; 2014 Oct; 124(15):2380-90. PubMed ID: 25157181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
    Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
    Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.
    Ismail A; Bandla S; Reveiller M; Toia L; Zhou Z; Gooding WE; Kalatskaya I; Stein L; D'Souza M; Litle VR; Peters JH; Pennathur A; Luketich JD; Godfrey TE
    Clin Cancer Res; 2011 Jul; 17(13):4513-22. PubMed ID: 21593195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inducible deletion of CDK4 and CDK6 - deciphering CDK4/6 inhibitor effects in the hematopoietic system.
    Maurer B; Brandstoetter T; Kollmann S; Sexl V; Prchal-Murphy M
    Haematologica; 2021 Oct; 106(10):2624-2632. PubMed ID: 32855282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
    Wu X; Yang X; Xiong Y; Li R; Ito T; Ahmed TA; Karoulia Z; Adamopoulos C; Wang H; Wang L; Xie L; Liu J; Ueberheide B; Aaronson SA; Chen X; Buchanan SG; Sellers WR; Jin J; Poulikakos PI
    Nat Cancer; 2021 Apr; 2(4):429-443. PubMed ID: 34568836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
    Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
    J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification of the DNA damage response by therapeutic CDK4/6 inhibition.
    Dean JL; McClendon AK; Knudsen ES
    J Biol Chem; 2012 Aug; 287(34):29075-87. PubMed ID: 22733811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
    Sharifi MN; Anandan A; Grogan P; O'Regan RM
    Cancer; 2020 Aug; 126(15):3400-3416. PubMed ID: 32426848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of CDK6 in cancer.
    Nebenfuehr S; Kollmann K; Sexl V
    Int J Cancer; 2020 Dec; 147(11):2988-2995. PubMed ID: 32406095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
    Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression.
    Scheidmann MC; Castro-Giner F; Strittmatter K; Krol I; Paasinen-Sohns A; Scherrer R; Donato C; Gkountela S; Szczerba BM; Diamantopoulou Z; Muenst S; Vlajnic T; Kunz L; Vetter M; Rochlitz C; Taylor V; Giachino C; Schroeder T; Platt RJ; Aceto N
    Cancer Res; 2022 Feb; 82(4):681-694. PubMed ID: 34916221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
    de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
    Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
    [No Abstract]   [Full Text] [Related]  

  • 38. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
    Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
    Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.
    Li F; Xu Y; Liu B; Singh PK; Zhao W; Jin J; Han G; Scott AW; Dong X; Huo L; Ma L; Pizzi MP; Wang Y; Li Y; Harada K; Xie M; Skinner HD; Ding S; Wang L; Krishnan S; Johnson RL; Song S; Ajani JA
    Clin Cancer Res; 2019 Apr; 25(7):2264-2277. PubMed ID: 30563933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.